Kyverna Therapeutics (KYTX) Other Non Operating Income (2023 - 2026)
Kyverna Therapeutics posted quarterly Other Non Operating Income of -$21000.0 for Q1 2026, up 22.22% year-on-year from -$17181.8 in Q1 2025, and down 223.53% on a QoQ basis from $17000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Other Non Operating Income data on file, last reported at -$21000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 22.22% year-over-year to -$21000.0; the trailing twelve-month figure through Mar 2026 stood at -$78000.0 (up 14.29% YoY), and the FY2025 full-year result was -$85000.0, up 5.56% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$21000.0, down from $17000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $17000.0 in Q4 2025 and bottomed at -$53000.0 in Q3 2025.
- The 4-year median for Other Non Operating Income is -$21000.0 (2025), against an average of -$19230.8.
- The widest annual swing landed in 2024, when Other Non Operating Income slumped 766.67%; it then surged 325.0% in 2025.
- A 4-year view of Other Non Operating Income shows it stood at -$32000.0 in 2023, then jumped by 112.5% to $4000.0 in 2024, then soared by 325.0% to $17000.0 in 2025, then slumped by 223.53% to -$21000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$21000.0 (Q1 2026), $17000.0 (Q4 2025), and -$53000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | -53,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | -27,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | -45,000.00 |
| Jun 30, 2024 | -23,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Dec 31, 2023 | -32,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2023 | -7,000.00 |
| Mar 31, 2023 | -3,000.00 |